What is the real-world uptake of SGLT2 inhibitors in patients with heart failure and reduced ejection fraction?
Real-world uptake of SGLT2 inhibitors in HFrEF patients has been rapid, increasing three-fold over 2 years, though further efforts are needed to ensure equitable implementation.
Use of SGLT2i increased three-fold over 2 years. Although this indicates a more rapid translation of trial results and guidelines into clinical practice compared to previous HF drugs, further efforts are advocated to complete the implementation process while avoiding inequities across different patient subgroups and discontinuations.
Stolfo et al. (Fri,) studied this question.